Oxford Cannabinoid Technologies Holdings Plc

OTCPK:OCTH.F Stock Report

Market Cap: US$3.0m

Oxford Cannabinoid Technologies Holdings Valuation

Is OCTH.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OCTH.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OCTH.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OCTH.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OCTH.F?

Key metric: As OCTH.F is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for OCTH.F. This is calculated by dividing OCTH.F's market cap by their current book value.
What is OCTH.F's PB Ratio?
PB Ratio1.2x
BookUK£1.95m
Market CapUK£2.38m

Price to Book Ratio vs Peers

How does OCTH.F's PB Ratio compare to its peers?

The above table shows the PB ratio for OCTH.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.7x
INM InMed Pharmaceuticals
0.4xn/aUS$2.8m
SNES SenesTech
0.6x15.2%US$2.3m
PTPI Petros Pharmaceuticals
0.8x33.6%US$2.5m
PCSA Processa Pharmaceuticals
0.8x-9.6%US$3.0m
OCTH.F Oxford Cannabinoid Technologies Holdings
1.2xn/aUS$3.0m

Price-To-Book vs Peers: OCTH.F is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (4.1x).

Price to Book Ratio vs Industry

How does OCTH.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.39m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.92m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.50m
OCTH.F 1.2xIndustry Avg. 1.7xNo. of Companies24PB012345+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: OCTH.F is good value based on its Price-To-Book Ratio (1.2x) compared to the US Pharmaceuticals industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is OCTH.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OCTH.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OCTH.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%